Karyopharm TherapeuticsKPTI
13F holders, Q1 2025 (March 31)2holders −85
0new positions
42sold out
$3.74avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Karyopharm Therapeutics Inc. (KPTI) in their 13F filings, down 85 from Q4 2024. 0 opened new positions and 42 sold out. The largest holders were Palo Alto Investors LP ($1.2M) and Birchview Capital, LP ($105K).
- Company
- Karyopharm Therapeutics Inc.
- CUSIP
- 48576U106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 42 | $5.5M |
All 13F filers, Q4 2024 → Q1 2025: 13,081,228 shares sold, net −13,081,228 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Palo Alto Investors LP | 0.23% | Reduce -93.4% | 324,032 | $1.2M |
| Birchview Capital, LP | 0.09% | Reduce -93.3% | 27,985 | $105K |
"% of holder's portfolio" is KPTI's weight in each manager's 13F, not the share of Karyopharm Therapeutics Inc. the manager owns.